Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
Haruhiko Ogata, Nobuo Aoyama, Seiichi Mizushima, Atsushi Hagino, Toshifumi Hibi
Intest Res. 2017;15(3):368-379.   Published online 2017 Jun 12     DOI:
Citations to this article as recorded by Crossref logo
Systematic review: safety of mesalazine in ulcerative colitis
P. Sehgal, J.-F. Colombel, A. Aboubakr, N. Narula
Alimentary Pharmacology & Therapeutics.2018; 47(12): 1597.     CrossRef